North America Cardiovascular Drugs Market

North America Cardiovascular Drugs Market Size (2024 to 2032)

The North America Oncology Drugs Market was worth USD 36.41 Billion in 2024 and is estimated to grow at a CAGR of 5.38% to reach USD 69.43 Billion by 2032.

Cardiovascular drugs are agents used to treat diseases associated with the circulatory system, including blood clots, stroke, coronary heart disease, hypertension/ hypotension, arrhythmias, high cholesterol, and heart failure. In North America, the cardiovascular drugs market is projected to be fuelled by Increased awareness of cardiovascular health and product introductions in technological healthcare sectors. Cardiovascular therapy entails a multifaceted strategy that may necessitate the use of a variety of drugs. Other driving factors in the market include a growth in the incidence of cardiovascular diseases and a growing need for more effective medicines. In addition, cardiovascular treatments have advanced significantly in research and development since they were first made available to the general public.

On the other hand, the major factors contributing to the growth are sedentary lifestyles with little physical activity, a poor diet, anxiety, and stress, all of which lead to chronic diseases such as diabetes and obesity, as well as an increase in the prevalence of multiple cardiovascular diseases such as CAD, strokes, and atrial fibrillation, necessitating effective CVD treatment. Recently, there has been a significant increase in innovative treatments introduced to the market, and they have proven successful. Moreover, the cardiovascular medication market may be considered cluttered with the presence of multiple significant firms and the growing effect of comparatively cheaper generics. However, cardiovascular disorders make them essentially incurable, and the increased prevalence makes therapy even more difficult for patients. This resulted in a significant unmet treatment requirement in the market, which is expected to be one of the market’s other important driving factors. The increased frequency of various coronary heart disorders such as stroke and cardiomyopathy, which causes a high number of cardiac deaths, and favorable reimbursement schemes are the primary reasons driving the growth of the North American cardiovascular drugs market. Several influential market leaders have introduced innovative medications to address the wide range of cardiovascular disease treatment needs. This leads to the cardiovascular drugs market.

However, The market is restrained by a decreasing target population and growing medication research costs. Despite the high frequency of cardiovascular illnesses, drug development pipelines have steadily declined for several reasons.

This research report on the North America cardiovascular drugs market has been segmented and sub-segmented into the following categories.

North America Cardiovascular Drugs Market Analysis By Drug Type

• Antihypertensive

• Antihyperlipidemic

• Anticoagulants

• Antiplatelet Drugs

• Others

North America Cardiovascular Drugs Market Analysis By Disease Indication

• Hypertension

• Hyperlipidemia

• Coronary Artery Disease

• Arrhythmia

• Others

North America Cardiovascular Drugs Market Analysis By End-Users

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

• Others

North America Cardiovascular Drugs Market Analysis By Country

• United States

• Canada

• Rest of North America

The North America cardiovascular drugs market is expected to dominate the entire market throughout the forecast period. This is due to the increased awareness of various heart diseases in the area. In addition, technological advancements in the healthcare sectors, increasing healthcare spending, and favorable reimbursement policies contribute to market growth. According to the Global Health and Wellness Report issued, approximately 40% of the adult population in the United States was diagnosed with a cardiovascular problem, resulting in an increased demand for highly effective and immediate treatment. As a result, the United States is the largest market for cardiovascular drugs, followed by Canada in North America.

The U.S. held the largest share of the cardiovascular market, and it is anticipated to continue its growth during the forecast period. The major factors contributing to the growth are sedentary lifestyles with little physical activity, a poor diet, anxiety, and stress, all of which lead to chronic diseases like diabetes and obesity, as well as an increase in the prevalence of multiple cardiovascular diseases such as CAD, strokes, and atrial fibrillation in the United States, necessitating effective CVD treatment.

According to the American Heart Association, nearly 92.1 million people in the United States suffered from cardiovascular diseases in 2018, with coronary artery disease (CAD) being the leading cause of death. This increased demand for better treatment with effective medication drove the market in the United States, which contributed to the market’s outstanding revenue share propelling the North America cardiovascular drugs market.

KEY MARKET PLAYERS

Merck & Co, Sanofi S.A., Pfizer Inc., Bristol-Myers Squibb Company, and Novartis AG are some noteworthy companies operating in the North America cardiovascular drugs market.